High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study

Blood Cancer J. 2022 Oct 28;12(10):145. doi: 10.1038/s41408-022-00740-3.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Azacitidine / therapeutic use
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Myelodysplastic Syndromes* / drug therapy
  • Treatment Outcome

Substances

  • Azacitidine